The Down Under medical community is abuzz with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in clinical trials for treating obesity. This medication https://thefairlist.com/story12038173/retatrutide-australia-a-emerging-prospect-for-weight-management